Cadrenal Therapeutics logo
Cadrenal Therapeutics
CVKD | NASDAQ
Chart Builder DCF Calculator
$1.40
-$0.11 (-7.28%)
At close: Nov 16, 2026, 4:00 PM ET
$1.57
+$0.17 (+12.39%)
After-hours: Nov 16, 2026, 7:42 PM ET

Cadrenal Therapeutics Company Profile

Company profile explained

Company Profile

Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.

Key Executives

Name Position
Quang X. Pham Chairman & Chief Executive Officer
Jeffrey Cole Chief Operating Officer
John Sharp Interim CFO & Principal Accounting Officer

Latest SEC Filings

Date Type Title
Oct 13, 2026 4 Filing
Oct 13, 2026 4 Filing
Oct 13, 2026 4 Filing
Oct 13, 2026 4 Filing
Oct 13, 2026 4 Filing
Oct 08, 2026 S-8 Filing
Oct 07, 2026 8-K Current Report
Sep 29, 2026 8-K Current Report
Sep 03, 2026 S-8 Filing
Aug 31, 2026 8-K Current Report
View All SEC Filings ➞
Cadrenal Therapeutics
Cadrenal Therapeutics logo
Country United States
IPO Date Jan 20, 2023
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Quang X. Pham

Contact Details

822 A1A North Ponte Vedra, Florida 32082 United States

Stock Details

Ticker Symbol CVKD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001937993
CUSIP Number 127636207
ISIN Number US1276362076
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.